PARP inhibitors in ovarian cancer: current status and future promise.
about
Management of relapsed ovarian cancer: a reviewProfile of olaparib in the treatment of advanced ovarian cancerDNA repair targeted therapy: The past or future of cancer treatment?Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapyCancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromesHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerOlaparib in the management of ovarian cancerProfile of veliparib and its potential in the treatment of solid tumorsOvarian cancer standard of care: are there real alternatives?Major clinical research advances in gynecologic cancer in 2014Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineToxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer: A network meta-analysis.PARP inhibitors in ovarian cancer: evidence, experience and clinical potentialDNA mismatch repair and oxidative DNA damage: implications for cancer biology and treatment.Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy.Molecular staging of gynecological cancer: What is the future?AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary diseaseMolecular biology of gynecological cancer.Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO).Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer.The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future.Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.The next steps in improving the outcomes of advanced ovarian cancer.Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.Current state of biomarkers in ovarian cancer prognosis.Veliparib for the treatment of ovarian cancer.Design, Synthesis, and Biological Evaluation of Novel PARP-1 Inhibitors Based on a 1H-Thieno[3,4-d] Imidazole-4-Carboxamide Scaffold.A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.PARP inhibitors as antitumor agents: a patent update (2013-2015).Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.Precision oncology: neither a silver bullet nor a dream.Advances in ovarian cancer therapy.Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.Nup153 and Nup50 promote recruitment of 53BP1 to DNA repair foci by antagonizing BRCA1-dependent events.Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.Poly(ADP-ribose) polymerase 1 searches DNA via a 'monkey bar' mechanism
P2860
Q26741755-05CD164B-839F-43D6-973D-1F408B3E87A7Q26749284-C468AC82-C675-486A-850D-4F03ED250886Q26768679-2241308C-B3FB-4500-A49D-C973BE64A14FQ26769604-07C29961-31BE-4022-958E-5590536F6A25Q26776258-7B31D85D-6733-4BFA-8C55-E6B1D7E49C97Q26783551-4ADD7423-D93A-486B-8F44-98F191CF727FQ26797166-DA42C555-0152-4BF3-9314-F9E8C4D0910DQ26801272-3C96F919-BBD7-49B3-84E3-FA69DA7ABFF9Q26862249-96846ADA-7088-4C80-AB70-BA0ED280ADC3Q26992183-9EDC14DD-5754-4AAF-87ED-A9125C4BC999Q28072204-24E00DFC-844D-462F-8912-48738DF1934AQ33438344-A5185D42-70ED-44E4-80C4-94C533586EDDQ33605912-87A96B03-020B-4769-8949-4DCE45A56CA8Q34309933-13FC61AB-B87A-41CA-8903-A2AFB04EF750Q35328194-4C0E0494-D974-4DA8-A0E6-F7BF0DF36B86Q35940829-206E7FEF-45A1-4BAE-B5B3-357EA11DBDA4Q36104522-C74CAEBA-7025-43F3-ADB8-0658CA788E04Q36245791-168333D4-2583-415D-AB9D-1E52DE599EC8Q36248459-82BB7A3D-C17D-43C0-A36A-FB78E599E629Q36502779-19FB3873-596C-48D8-8945-CB8407C27711Q36893991-81CF43C2-6DF4-4ACF-91D5-775B2228EA78Q37470280-BBD1A152-F031-4C1D-839F-C962157AA8E4Q37745944-88A935AF-6472-4AC1-A915-2E1A98164A51Q38282823-05D8915A-2FE7-4910-B0F6-7837EA74BCDEQ38340008-999FB56F-185D-4169-87BA-139A388D11CBQ38377713-5AA3A54F-5E7C-4337-A6B4-59A9F6CCA394Q38535374-6583E812-CE0B-4495-9622-4F1F340A3E08Q38609944-D90FD9ED-B6CE-4831-A352-E4CFBD6BB193Q38628964-16E84FEA-767F-4D2C-B554-4E4571E2B2D6Q38710466-FA22466D-6656-4E47-A892-1FCA3A1FFFBCQ38764341-A8C2AD5C-E149-4F9B-99F8-A4316B357D7DQ38780396-488A4A56-D5E4-4356-8D2E-629699FDC556Q38795712-7B7D2083-DC01-4161-8AE7-EDE3355D0386Q40035188-6DA62D4D-5C81-46DF-B9CD-FFF830AF986EQ47737073-FA06E048-C31A-41BA-A8F8-B17DC7FEA16BQ48104995-C3A4AB89-C632-4C59-8FDD-B167E5FAEC04Q48110433-4ADC7DC7-50A7-4D88-A782-9143085F04CBQ48333916-5CB1167C-7FC9-4B90-A10E-4EC4B1DBA9A0Q52941950-BF1BC7B5-986A-4275-84B3-E562DDD616F9Q58794907-F5D14F85-3C9C-4E97-AA94-4A928F9E27B2
P2860
PARP inhibitors in ovarian cancer: current status and future promise.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
PARP inhibitors in ovarian cancer: current status and future promise.
@en
type
label
PARP inhibitors in ovarian cancer: current status and future promise.
@en
prefLabel
PARP inhibitors in ovarian cancer: current status and future promise.
@en
P2093
P1433
P1476
PARP inhibitors in ovarian cancer: current status and future promise.
@en
P2093
Joyce F Liu
Panagiotis A Konstantinopoulos
Ursula A Matulonis
P304
P356
10.1016/J.YGYNO.2014.02.039
P407
P577
2014-03-04T00:00:00Z